PTC 3rd Quarter 2026 Financial Results - PTC THERAPEUTICS INC

Financial Performance:

• Total revenue for Q3 2026 reached $358 million, driven by $276 million in product revenue (a 100%+ year-over-year increase from $131 million in Q3 2025).
• Sufiance (formerly Defiance) generated $182 million in Q3 revenue, with over 2,000 active patients globally.
• Mature franchise revenue totaled $74 million, split between Translarna ($49 million, including a Russia government order) and Impaza ($25 million).
• Royalty revenue from Roche's Kuvan/Tri-Lynx portfolio was $82 million, derived from $607 million in Roche's global revenue.
• Non-GAAP R&D expenses were $95 million, and Non-GAAP SG&A expenses were $67 million for the quarter.
• Cash, cash equivalents, and marketable securities stood at $2.13 billion as of September 30, 2026.
• The company acquired the BLA-stage Fabry gene therapy asset ST920 for an upfront payment of $111 million.

Guidance and Future Outlook:

• Full-year 2026 product revenue guidance raised to $960–$990 million, reflecting 64–69% year-over-year growth.
• Total revenue guidance raised to $1.29–$1.32 billion for 2026.
• Management expects to achieve cash flow breakeven in 2026.
• Sufiance is projected to have a long-term peak sales opportunity of over $2 billion globally.
• ST920 is expected to become accretive in 2027 following a potential commercial launch.
• International revenue growth is anticipated to accelerate in 2027 as pricing and reimbursement are secured in new markets (Europe, Latin America, Middle East).

Business Segments and Product Lines:

• Sufiance: Revenue driven by therapy-naive adults, patients switching from branded/generic KUVAN, and new patient starts in international markets; adherence remains strong with low 20% cumulative discontinuation rates.
• ST920 (Fabry): A once-administered AAV gene therapy acquired for BLA submission in Q4 2026, targeting accelerated approval in 2027; demonstrates increased alpha-gal activity and improved renal function.
• Vodafon (Huntington's): Type C FDA meeting rescheduled for Q1 2027; Phase 3 PIVOT-HD trial enrolling ~770 patients with an interim analysis planned.
• PTC844 (RA): Phase 2A study initiated in adults with Rheumatoid Arthritis to confirm DHO-DH inhibition and B/T-cell immunity effects.
• PTC612 (NLRP3): Phase 1 study progressing well with initial dosing; development focused on rare pulmonary indications.
• PTC303 (Splicing): Candidate targeting MSH3 for triplet repeat expansion disorders (DM-1, Huntington's); expected to enter clinic in 2027.
• Translarna & Impaza: Continued revenue generation despite generic competition; Impaza facing price pressure from new generic entrants in the U.S.

Market and Competitive Landscape:

• Sufiance is capturing market share from the incumbent KUVAN (BH4) therapy, with over 85% of the 17,000 U.S. PKU patient population yet to try the product.
• International expansion includes strong performance in Japan and active negotiations in Germany, France, Spain, and Italy.
• The Fabry disease market is characterized by significant unmet need, with many patients currently untreated or on less effective Enzyme Replacement Therapies (ERT).
• Management views the FDA's recent focus on tailored trials for rare diseases as a favorable shift in the regulatory landscape.

Risks and Challenges:

• Generic competition is impacting Impaza revenue and pricing dynamics in the U.S.
• Potential delays in international pricing and reimbursement negotiations could slow ex-U.S. growth.
• Regulatory timelines for pipeline assets (e.g., Vodafon Type C meeting delay to Q1 2027) are subject to FDA scheduling constraints.
• Large-scale patient switches from KUVAN face logistical hurdles, including limited clinic throughput and varying insurance coverage requirements.

Management Commentary and Tone:

• Tone was highly confident and optimistic, characterized by a view that the Sufiance launch is still in the "very early innings" despite record Q3 performance.
• Management emphasized "steady, durable growth" rather than acceleration, highlighting the transition from initial launch to broader market penetration.
• Strong emphasis on the differentiated clinical profile of Sufiance (diet liberalization, cognitive improvement) driving patient adherence and prescriber enthusiasm.
• Confident in the ability to leverage existing commercial infrastructure for the upcoming ST920 launch.

Analyst Questions and Answers:

• Launch Stage: Management confirmed being in early stages of Sufiance adoption, with <4% global penetration (2,000 of 58,000 patients) and a long path to the $2B peak.
• Geographic Split: Expected peak revenue will be majority U.S.-driven due to higher price points, despite a larger patient count internationally.
• Q4 Guidance: Raised guidance primarily due to Sufiance momentum; mature franchise (Impaza/Translarna) expected to contribute less in Q4 due to generic pressure and the lack of repeat government orders.
• ST920 Pricing/Access: Focus on demonstrating long-term durability and quality of life improvements to justify the one-time gene therapy cost versus recurring ERT.
• Adherence: Renewal rates remain high (~90%); discontinuation rates are stabilizing in the low 20%, with expectations for even higher adherence among switch patients.
• Vodafon Trial Design: PIVOT-HD trial is robust enough to serve as a confirmatory study regardless of accelerated approval status; priority review for ST920 is possible due to RMAT designation.

Other Key Points:

• Sufiance has demonstrated efficacy in classical PKU patients and those with non-BH4 responsive mutations, broadening the treatable population.
• Patient advocacy groups for Fabry disease have expressed strong support for ST920's gene therapy approach.
• Management highlighted the success of "ambassador programs" and peer-to-peer social media engagement in driving patient discovery and switching.
• The company remains disciplined in Business Development, utilizing its $2B+ cash balance strategically to create shareholder value.